Vertex Software faces strong competition and slower growth, leading to a neutral rating. See why VERX stock remains pricey ...

Vertex is ending work on one of its two clinical-stage islet cell treatments after the diabetes therapy looked unlikely to ...

Despite a $400 million impairment charge, analysts say the removal of a drug-device combo from its portfolio is not a huge ...

Vertex Pharmaceuticals generated more than $11 billion in product revenue last year thanks to its dominance in cystic fibrosis treatment. Progress in that specialty area and two key drug approvals ...

Vertex's cloud growth momentum remains strong, with a 27% y/y increase in 4Q24. Read more to see why I upgrade VERX stock ...

In the latest development, Google today announced that it would be adding Chirp 3 — its speech-to-text and HD text-to-speech models — to its Vertex AI development platform starting next week.

Vertex has doubled down on cell-based therapies for type 1 diabetes (T1D), buying ViaCyte in a $320 million deal that it says will accelerate development of its own candidate VX-880. The deal has ...

The expanded collaboration now allows Reddit to use Google’s Vertex AI, which enables users to build, deploy, and scale machine learning models and AI applications, the author notes. Easily ...